Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT01506609
Trial Phases:	Phase II	Protocol IDs:	M12-895 (primary) 2011-002913-12
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Abbvie
NCI Full Details:	http://clinicaltrials.gov/show/NCT01506609

Summary

The primary objective of the study is to assess the progression-free survival (PFS) of oral
veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared
to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and
locally recurrent or metastatic breast cancer.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.